Skip to main content
SpringerLink
Log in

Effects of Acebutolol on the Serum Lipid Profile

  • Published:
Drugs Aims and scope Submit manuscript

Summary

Epidemiological and recent interventional studies have emphasised the relationship between plasma lipid parameters and the incidence of coronary heart disease.

β-Blockers, particularly those without intrinsic sympathomimetic activity (ISA), are generally reported to increase triglyceride levels and decrease high density lipoprotein (HDL)-cholesterol levels, both changes theoretically increasing the risk of coronary heart disease.

A review of all published trials concerning the effects of acebutolol (a cardioselective β-blocker with mild ISA) on the plasma lipid profile was carried out, with a particular emphasis on studies reporting a comparison with other β-blockers. The results indicate that, on average, acebutolol does not have any adverse effects on plasma lipids and may even reduce total and low density lipoprotein (LDL)-cholesterol by 7 and 5%, respectively. In contrast, the other β-blockers compared under the same conditions (propranolol, pindolol and Penbutolol) tended to increase triglyceride levels (+19% when compared with acebutolol) and decrease HDL-cholesterol (−7% when compared with acebutolol) to an extent that was consistent with previous reports in the literature.

In interpreting these differences in lipid parameters in the light of epidemiological and interventional study data, the use of acebutolol as opposed to the other β-blockers could theoretically lead to a relative reduction in coronary risk of 20% or more.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  • Amery A, Fagard R, Staessen J. Recent data on changes in lipid metabolism induced by hypotensive drugs. Current Opinion in Cardiology 2: 769–774, 1987

    Article  Google Scholar 

  • Ames RP. The effects of antihypertensive drugs on serum lipids and lipoproteins. I. Diuretics. Drugs 32: 260–278, 1986a

    Article  PubMed  CAS  Google Scholar 

  • Ames RP. The effects of antihypertensive drugs on serum lipids and lipoproteins. II. Non-diuretic drugs. Drugs 32: 335–357, 1986b

    Article  PubMed  CAS  Google Scholar 

  • Birnbaum J, Di Bianco R, Becker KL, Muesing R, Costello RB, et al. Glucose and lipid metabolism during acebutolol and propranolol therapy of angina in nondiabetic patients. Clinical Pharmacology and Therapeutics 33: 294–300, 1983

    Article  PubMed  CAS  Google Scholar 

  • Carlson LA. On the use of nicotinic acid — the broad spectrum hypolipidaemic agent — in primary hyperlipidaemias and in secondary prevention of myocardial infarction. International Symposium on Cholesterol Control and Cardiovascular Diseases: Prevention and Therapy, Milan, 7–9 July, 1987. Abstract, pp. 19–21, 1987

  • Coronary Drug Project Research Group. Fifteen year mortality in coronary drug project patients: long-term benefit with niacin. American Journal of Cardiology 8: 1245–1255, 1986

    Article  Google Scholar 

  • Day JL, Metcalf J, Simpson CN. Adrenergic mechanisms in control of plasma lipid concentrations. British Medical Journal 284: 1145–1148, 1982

    Article  PubMed  CAS  Google Scholar 

  • Delong DM, Delong ER, Wood PD, Lippel K, Rifkind BM. A comparison of methods for the estimation of plasma low- and very low-density lipoprotein cholesterol. Journal of the American Medical Association 256: 2372–2377, 1986

    Article  PubMed  CAS  Google Scholar 

  • Frick MH, Elo O, Haapa K, Heinonen OP, Heinsalmi P, et al. Helsinki heart study: primary prevention trial with gemfibrozil in middle-aged men with dyslipidaemia. New England Journal of Medicine 317: 1237–1245, 1987

    Article  PubMed  CAS  Google Scholar 

  • Giuntoli F, Scalabrino A, Galeone F, Birindelli A, Natali A, et al. Antihypertensive and metabolic effects of a long-term treatment with acebutolol. Current Therapeutic Research 36: 188–194, 1984

    Google Scholar 

  • Gordon T, Kannel WB. Multiple risk functions for predicting coronary heart disease: the concept, accuracy and application. American Heart Journal 103: 1031–1039, 1982

    Article  PubMed  CAS  Google Scholar 

  • Hagel F, Ulm K. Einfluss einer achtwöchigen betablockertherapie auf kreislauf und Fettstoffwechselparameter. Medizinische Welt 34: 1370–1372, 1983

    PubMed  CAS  Google Scholar 

  • Hulley SB, Rosenman RH, Bawol RD, Brand RJ. Epidemiology as a guide to clinical decisions: the association between triglyceride and CHD. New England Journal of Medicine 302: 1383–1389, 1980

    Article  PubMed  CAS  Google Scholar 

  • Ieri T, Banba N, Kase N, Kobori H, Kiyota M, et al. Effects of acebutolol on the serum levels of lipids in hypertensives. Journal of the Japanese Atherosclerotic Society 13: 305–310, 1985

    Google Scholar 

  • Jaillard J. La surveillance du bilan lipidique plasmatique chez les diabétiques hypertendus traités par acébutolol. Gazette Médicale de France 89: 4572–4576, 1982

    Google Scholar 

  • Jiao S, Nakajima T, Kameda K, Tokunaga K, Kubo M, et al. Effect of acebutolol on serum lipid levels — combination therapy of acebutolol with thiazide diuretics. Therapeutic Research 5: 913–920, 1986

    Google Scholar 

  • Kannel WB, Castelli WP, Gordon T, McNamara PM. Serum cholesterol, lipoproteins and the risk of coronary heart disease. Annals of Internal Medicine 74: 1–12, 1971

    PubMed  CAS  Google Scholar 

  • Krauss RM, Lindgren FT, Williams PT, Kelsey SF, Brensike J, et al. Intermediate-density lipoproteins and progression of coronary artery disease in hypercholesterolaemic men. Lancet II: 62–66, 1987

    Article  Google Scholar 

  • Lehtonen A. The effect of acebutolol on plasma lipids, blood glucose and serum insulin levels. Acta Medica Scandinavica 216: 57–60, 1984

    Article  PubMed  CAS  Google Scholar 

  • Lehtonen A. The effect of acebutolol on plasma apoproteins and HDL cholesterol subfractions. Research Communications in Chemical Pathology and Pharmacology 47: 427–435, 1985

    PubMed  CAS  Google Scholar 

  • Lehtonen A, Viikari J. Long-term effect of Sotalol on plasma lipids. Clinical Science 57: 405s–407s, 1979

    PubMed  Google Scholar 

  • Levy RI, Brensike JF, Epstein SE, Kelsey SF, Passamani ER. The influence of changes in lipid values induced by cholestyramine and diet on progression of coronary artery disease: results of the NHLBI type II coronary intervention study. Circulation 69: 325–337, 1984

    Article  PubMed  CAS  Google Scholar 

  • Lipid Research Clinics Program. The Lipid Research Clinics Coronary Primary Prevention Trial results. Journal of the American Medical Association 251: 351–374, 1984

    Article  Google Scholar 

  • Manin’t Veld AJ, Schalekamp MADH. On the antihypertensive mechanisms of beta-adrenoreceptor antagonists in relation to intrinsic sympathomimetic activity, cardioselectivity and hydrophilicity. Journal de Pharmacologie 14(Suppl. II): 69–104, 1983

    Google Scholar 

  • Matsumoto A, Nakamura T. Effects of beta-blockers on serum lipid metabolism. A comparative study of propranolol, pindolol and acebutolol. Japanese Journal of Pharmacological Therapy 14: 269–274, 1986

    Google Scholar 

  • Miller NE. Effects of adrenoreceptor blocking drugs on plasma lipoprotein concentrations. American Journal of Cardiology 60 (Suppl.): 17E–23E, 1987

    Article  PubMed  CAS  Google Scholar 

  • Miller NE, Nanjee MN, Rajput-Williams J, Coltart DJ. Double-blind trial of the long-term effects of acebutolol and propranolol on serum lipoproteins in patients with stable angina pectoris. American Heart Journal 114: 1007–1010, 1987

    Article  PubMed  CAS  Google Scholar 

  • Nakamura H. Effects of antihypertensive drugs on plasma lipids. American Journal of Cardiology 60 (Suppl.): 24E–28E, 1987

    Article  PubMed  CAS  Google Scholar 

  • Pocock SJ. Current issues in the design and interpretation of clinical trials. British Medical Journal 290: 39–42, 1985

    Article  PubMed  CAS  Google Scholar 

  • Rose G. Review of primary prevention trials. American Heart Journal 114: 1013–1029, 1987

    Article  PubMed  CAS  Google Scholar 

  • Rouffy J. Acébutolol et métabolisme lipidique. Journal of the American Medical Association, Supplément Edition Française, Décembre: 30, 1985

  • Scotti A, Lucchini M, Recchia M. Indagine multicentria sulla terapia dell’ipertensone arteriosa con acebutolol. Biologica Medica 5: 43–70, 1983

    Google Scholar 

  • Shulman RS, Herbert PN, Capone RJ, McClure D, Hawkins CM, et al. Effects of propranolol on blood lipids and lipoproteins in myocardial infarction. Circulation 67(Suppl. I): I–19–1–21, 1983

    Google Scholar 

  • Singh BN, Thoden WR, Hard A. Acebutolol. A review of its pharmacological properties and therapeutic efficacy in hypertension, angina pectoris and arrhythmia. Drugs 29: 531–569, 1985

    Article  PubMed  CAS  Google Scholar 

  • Stamler J, Princeas RJ, Neaton JD, Grimm RH, McDonald RH, et al. Background and design of the new US trial on diet and drug treatment of ‘mild’ hypertension (TOMHS). American Journal of Cardiology 59 (Suppl.): 514–604, 1987

    Article  Google Scholar 

  • Steiner G. Hypertriglyceridaemia and carbohydrate intolerance: interrelations and therapeutic implications. American Journal of Cardiology 57 (Suppl.): 274–304, 1986

    Article  Google Scholar 

  • Wahl J, Singh BN, Thoden WR. Comparative hypotensive effects of acebutolol and hydrochlorothiazide in patients with mild to moderate essential hypertension: a double-blind multicenter evaluation. American Heart Journal 111: 353–362, 1986

    Article  PubMed  CAS  Google Scholar 

  • Weidmann P, Uehlinger DE, Gerber A. Antihypertensive treatment and serum lipoproteins. Journal of Hypertension 3: 297–306, 1985

    Article  PubMed  CAS  Google Scholar 

  • Wilcox RG, Mitchell JR, Hampton JR. Treatment of high blood pressure: should clinical practice be based on results of clinical trials? British Medical Journal 293: 433–437, 1986

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Rhône-Poulenc Santé, 20, avenue Raymond-Aron, 92165, Antony Cedex, France

    Alan Clucas

  2. Bowman Gray School of Medicine, Winston Salem, North Carolina, USA

    Norman Miller

Authors
  1. Alan Clucas
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Norman Miller
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Clucas, A., Miller, N. Effects of Acebutolol on the Serum Lipid Profile. Drugs 36 (Suppl 2), 41–50 (1988). https://doi.org/10.2165/00003495-198800362-00008

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00003495-198800362-00008

Keywords

Search

Navigation